Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
16 Octobre 2024 - 10:15PM
Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company,
announced today that CEO Josh Riggs is scheduled to present at the
17th annual Main Event, hosted by LD Micro, on Tuesday, October
29th in Los Angeles.
Oncocyte management will also be available for one-on-one
meetings with investors. To schedule a one-on-one meeting, please
contact Julie Silber at PCG Advisory (jsilber@pcgadvisory.com) or
request a meeting via the LD Micro Conference platform.
Event: LD Micro Main Event
XVIIDate: Tuesday, October
29thPresentation Time: 2:30 PM
PTLocation: The Luxe Sunset Boulevard Hotel, Los
Angeles
To register to watch the virtual presentation, please
click here.
Summary of LD Micro Main Event XVIIThe 2024 LD
Micro Main Event XVII will run from October 28th to
the 30th at the Luxe Sunset Boulevard Hotel in Los
Angeles. Registration begins at 3:00 PM PT on October 28th followed
by keynotes and happy hour. Presentations will run from 8:00 AM PT
to 5:00 PM PT on October 29th and 30th. This three-day event will
feature around 150 companies, presenting in half-hour increments,
and attending private meetings with investors.
About LD MicroLD Micro, a wholly owned
subsidiary of Freedom US Markets, was founded in 2006 with the sole
purpose of being an independent resource in the micro-cap space.
Through the LD Micro Index and annual investor conferences, LD has
served as an invaluable asset to all those interested in
discovering the next generation of great companies. For more
information on LD Micro, visit www.ldmicro.com.
About OncocyteOncocyte is a
diagnostics technology company. The Company’s tests are designed to
help provide clarity and confidence to physicians and their
patients. VitaGraft™ is a clinical blood-based solid organ
transplantation monitoring test. GraftAssure™ is a research use
only (RUO) blood-based solid organ transplantation monitoring test.
DetermaIO™ is a gene expression test that assesses the tumor
microenvironment to predict response to immunotherapies.
DetermaCNI™ is a blood-based monitoring tool for monitoring
therapeutic efficacy in cancer patients. For more information
about Oncocyte, please visit https://oncocyte.com/. For
more information about our products, please visit the following web
pages:
VitaGraft Kidney™
- https://oncocyte.com/vitagraft-kidney/VitaGraft
Liver™
- https://oncocyte.com/vitagraft-liver/GraftAssure™
- https://oncocyte.com/graftassure/DetermaIO™
- https://oncocyte.com/determa-io/DetermaCNI™
- https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are
trademarks of Oncocyte Corporation.
CONTACT:Jeff RamsonPCG Advisory(646)
863-6893jramson@pcgadvisory.com
Oncocyte (NASDAQ:OCX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Oncocyte (NASDAQ:OCX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024